Journal of Developing Drugs
Open Access

Healthcare transformations and disruptions in the biopharma industry: The future of biosimilars

Joint Event on 14^th International Conference on Generic Drugs and Biosimilars & 9^th Global Experts Meeting on Neuropharmacology

November 15-16, 2018 | Berlin, Germany

Reenita Das

Frost & Sullivan, USA

Keynote: J Dev Drugs

Abstract :

This presentation will provide the top growth drivers that are changing the pharma landscape and the impact of digital transformation in this industry. It will also examine the future landscape for biosimilars and the potential growth opportunities and new business models. Specifically in Europe, it is expected to remain the largest contributor to biosimilars revenue worldwide for the next 5-7 years as a number of biologic drugs are going to lose their exclusivity. Hence, this will significantly reduce costs for patients and health system.

Biography :

Reenita Das is a healthcare futurist and strategist, passionate about changing the healthcare industry. She is currently working as Transformational Health Partner and Senior Vice President and is the first woman Partner at Frost & Sullivan. In addition, she is the Founder of GLOW (Growth and Innovation of Women) program. She is also on the Board of a non-project “High Tech High Heels” Silicon Valley that focuses on increasing gender diversity for STEM. In her current role, she works on futuristic scenarios and forecasts in understanding how healthcare will operate 10 years from today, working with clients on the impact of these mega trend changes to their business. She is focused heavily on rethinking consumer business models as healthcare makes a transition to health and identifying opportunities with companies outside of healthcare to bring solutions to the healthcare sector. She is also focusing heavily on showcasing “Femtech” and the growth opportunities from that new sector.

E-mail: reenita_das@frost.com